Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

Inter- and intra-observer reproducibility of ADC measurements in esophageal carcinoma primary tumors.

Ye Z, Fang J, Dai S, Xie T, Wang F, Wang Z, Li K, Fu Z, Wang Y.

Oncotarget. 2017 Oct 6;8(54):92880-92889. doi: 10.18632/oncotarget.21639. eCollection 2017 Nov 3.

2.

What is the optimal radiation dose for non-operable esophageal cancer? Dissecting the evidence in a meta-analysis.

Chen Y, Zhu HP, Wang T, Sun CJ, Ge XL, Min LF, Zhang XW, Jia QQ, Yu J, Yang JQ, Allgayer H, Abba ML, Zhang XZ, Sun XC.

Oncotarget. 2017 Jun 28;8(51):89095-89107. doi: 10.18632/oncotarget.18760. eCollection 2017 Oct 24.

3.
4.

A Pilot Study of Chemoradiotherapy With Weekly Docetaxel for Thoracic Esophageal Carcinoma With T4 and/or M1 Lymph Node Metastasis.

Makino I, Ninomiya I, Okamoto K, Kinoshita J, Hayashi H, Nakamura K, Oyama K, Nakagawara H, Fujita H, Tajima H, Takamura H, Kitagawa H, Fushida S, Tani T, Fujimura T, Ohta T, Takanaka T.

World J Oncol. 2011 Oct;2(5):252-258. doi: 10.4021/wjon407w. Epub 2011 Oct 28.

5.

A phase II study of S-1 with concurrent radiotherapy in elderly patients with esophageal cancer.

Ji Y, Du X, Tian Y, Sheng L, Cheng L, Chen Y, Qiu G, Zhou X, Bao W, Zhang D, Chen M.

Oncotarget. 2017 Sep 15;8(47):83022-83029. doi: 10.18632/oncotarget.20938. eCollection 2017 Oct 10.

6.

Clinical outcomes of intensity modulated proton therapy and concurrent chemotherapy in esophageal carcinoma: a single institutional experience.

Prayongrat A, Xu C, Li H, Lin SH.

Adv Radiat Oncol. 2017 Jun 13;2(3):301-307. doi: 10.1016/j.adro.2017.06.002. eCollection 2017 Jul-Sep.

7.

Improved survival with higher radiation dose for esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy.

Deng Y, Bian C, Tao H, Zhang H.

Oncotarget. 2017 Jul 6;8(45):79662-79669. doi: 10.18632/oncotarget.19030. eCollection 2017 Oct 3.

8.

Shifting practice in definitive chemoradiation for localized esophageal cancer.

Qu XM, Biagi JJ, Hopman WM, Mahmud A.

Curr Oncol. 2017 Oct;24(5):e379-e387. doi: 10.3747/co.24.3677. Epub 2017 Oct 25.

9.

Treatment outcomes of extended-field radiation therapy for thoracic superficial esophageal cancer.

Lee DY, Moon SH, Cho KH, Kim TH, Kim MS, Lee JY, Suh YG.

Radiat Oncol J. 2017 Sep;35(3):241-248. doi: 10.3857/roj.2017.00458. Epub 2017 Sep 29.

10.

Prognostic value of supraclavicular nodes and upper abdominal nodes metastasis after definitive chemoradiotherapy for patients with thoracic esophageal squamous cell carcinoma.

Li X, Zhao L, Zhang W, Yang C, Lian Z, Wang S, Liu N, Pang Q, Wang P, Yu J.

Oncotarget. 2017 May 19;8(39):65171-65185. doi: 10.18632/oncotarget.18015. eCollection 2017 Sep 12.

11.

Zoledronic acid augments the radiosensitivity of cancer cells through perturbing S- and M-phase cyclins and p21CIP1 expression.

Du C, Wang Y, Li H, Huang Y, Jiang O, You Y, Luo F.

Oncol Lett. 2017 Oct;14(4):4237-4242. doi: 10.3892/ol.2017.6710. Epub 2017 Aug 3.

12.

Definitive chemoradiotherapy.

Stahl M, Budach W.

J Thorac Dis. 2017 Jul;9(Suppl 8):S792-S798. doi: 10.21037/jtd.2017.05.05. Review.

13.

Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity.

Haefner MF, Lang K, Verma V, Koerber SA, Uhlmann L, Debus J, Sterzing F.

Radiat Oncol. 2017 Aug 15;12(1):131. doi: 10.1186/s13014-017-0863-3.

14.

DVH- and NTCP-based dosimetric comparison of different longitudinal margins for VMAT-IMRT of esophageal cancer.

Münch S, Oechsner M, Combs SE, Habermehl D.

Radiat Oncol. 2017 Aug 15;12(1):128. doi: 10.1186/s13014-017-0871-3.

15.

Chemoradiation therapy with docetaxel in elderly patients with stage II/III esophageal cancer: A phase 2 trial.

Ohba A, Kato K, Ito Y, Katada C, Ishiyama H, Yamamoto S, Ura T, Kodaira T, Kudo S, Tamaki Y.

Adv Radiat Oncol. 2016 Jul 15;1(4):230-236. doi: 10.1016/j.adro.2016.07.002. eCollection 2016 Oct-Dec.

16.

Esophageal motion characteristics in thoracic esophageal cancer: Impact of clinical stage T4 versus stages T1-T3.

Kobayashi Y, Myojin M, Shimizu S, Hosokawa M.

Adv Radiat Oncol. 2016 Aug 23;1(4):222-229. doi: 10.1016/j.adro.2016.08.006. eCollection 2016 Oct-Dec.

17.

Primary radio(chemo)therapy for esophageal cancer in elderly patients: are efficiency and toxicity comparable with younger patients?

Münch S, Heinrich C, Habermehl D, Oechsner M, Combs SE, Duma MN.

Eur J Med Res. 2017 Jul 6;22(1):24. doi: 10.1186/s40001-017-0265-x.

18.

Long-term outcome of concurrent chemoradiotherapy with elective nodal irradiation for inoperable esophageal cancer.

Jing Z, Chen T, Zhang X, Wu S.

Cancer Sci. 2017 Sep;108(9):1828-1833. doi: 10.1111/cas.13308. Epub 2017 Jul 27.

19.

Outcome of proximal esophageal cancer after definitive combined chemo-radiation: a Swiss multicenter retrospective study.

Herrmann E, Mertineit N, De Bari B, Hoeng L, Caparotti F, Leiser D, Jumeau R, Cihoric N, Jensen AD, Aebersold DM, Ozsahin M.

Radiat Oncol. 2017 Jun 14;12(1):97. doi: 10.1186/s13014-017-0834-8.

20.

Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo.

Ma J, Li N, Zhao J, Lu J, Ma Y, Zhu Q, Dong Z, Liu K, Ming L.

Oncol Lett. 2017 Jun;13(6):4868-4874. doi: 10.3892/ol.2017.6069. Epub 2017 Apr 21.

Supplemental Content

Support Center